China Pharma Holdings (CPHI) Accumulated Expenses (2010 - 2026)

China Pharma Holdings (CPHI) has reported Accumulated Expenses for 17 consecutive years, with $1.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accumulated Expenses rose 20.7% year-over-year to $1.9 million; the trailing twelve-month figure through Jun 2026 stood at $1.9 million (up 20.7% YoY), and the FY2025 full-year result was $1.9 million, up 20.91% from the prior year.
• Accumulated Expenses rose to $1.9 million in Q2 2026 per CPHI's latest filing, from $1.9 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $1.9 million in Q2 2026 and bottomed at $110387.0 in Q2 2022.
• Historically, Accumulated Expenses has averaged $896940.9 across 5 years, with a median of $830156.5 in 2022.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses sank 66.79% in 2022, then jumped 1291.8% in 2025.
• Over 5 years, Accumulated Expenses stood at $404807.0 in 2022, then jumped by 210.15% to $1.3 million in 2023, then climbed by 26.44% to $1.6 million in 2024, then gained by 20.91% to $1.9 million in 2025, then rose by 0.83% to $1.9 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $1.9 million, $1.9 million, and $1.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.